Index RUT
P/E -
EPS (ttm) -1.68
Insider Own 18.58%
Shs Outstand 256.14M
Perf Week -9.56%
Market Cap 2.87B
Forward P/E -
EPS next Y -0.72
Insider Trans 0.00%
Shs Float 247.13M
Perf Month -11.92%
Income -440.22M
PEG -
EPS next Q -0.30
Inst Own 68.27%
Short Float 23.34%
Perf Quarter 10.90%
Sales 32.77M
P/S 87.62
EPS this Y 31.97%
Inst Trans -1.80%
Short Ratio 8.17
Perf Half Y -35.78%
Book/sh 2.58
P/B 3.66
EPS next Y 44.22%
ROA -51.14%
Short Interest 57.69M
Perf Year 58.72%
Cash/sh 1.36
P/C 6.96
EPS next 5Y -
ROE -65.36%
52W Range 3.21 - 18.33
Perf YTD 16.36%
Dividend Est. -
P/FCF -
EPS past 5Y -8.25%
ROI -52.48%
52W High -48.39%
Beta 0.65
Dividend TTM -
Quick Ratio 4.85
Sales past 5Y 0.00%
Gross Margin -124.49%
52W Low 194.70%
ATR (14) 0.66
Dividend Ex-Date -
Current Ratio 5.15
EPS Y/Y TTM 25.12%
Oper. Margin -1401.36%
RSI (14) 42.23
Volatility 7.74% 6.03%
Employees 557
Debt/Eq 0.11
Sales Y/Y TTM 13669.75%
Profit Margin -1343.27%
Recom 1.50
Target Price 22.90
Option/Short Yes / Yes
LT Debt/Eq 0.09
EPS Q/Q 28.17%
Payout -
Rel Volume 0.55
Prev Close 9.35
Sales Surprise 26.47%
EPS Surprise 3.82%
Sales Q/Q 12969.75%
Earnings Aug 08 AMC
Avg Volume 7.06M
Price 9.46
SMA20 -12.79%
SMA50 0.40%
SMA200 -7.21%
Trades
Volume 3,968,165
Change 1.18%
Date
Action
Analyst
Rating Change
Price Target Change
Jul-29-24 Downgrade
Piper Sandler
Overweight → Neutral
$19 → $10
Nov-20-23 Initiated
Goldman
Buy
$12
Sep-18-23 Reiterated
Barclays
Overweight
$40 → $18
May-30-23 Upgrade
Wells Fargo
Equal Weight → Overweight
$11 → $17
Mar-27-23 Resumed
Wells Fargo
Equal Weight
$11
Jan-27-23 Upgrade
Piper Sandler
Neutral → Overweight
$11 → $14
Dec-09-22 Downgrade
Goldman
Buy → Neutral
$20 → $6
Oct-31-22 Initiated
Guggenheim
Neutral
Aug-18-22 Resumed
Wells Fargo
Equal Weight
$14
Jan-28-22 Upgrade
Stifel
Hold → Buy
$23 → $25
Dec-07-21 Resumed
Cowen
Outperform
Jun-10-21 Upgrade
JMP Securities
Mkt Perform → Mkt Outperform
$32
May-20-21 Downgrade
Piper Sandler
Overweight → Neutral
$35 → $18
May-19-21 Downgrade
Stifel
Buy → Hold
May-19-21 Downgrade
JMP Securities
Mkt Outperform → Mkt Perform
May-03-21 Initiated
Truist
Buy
$50
Apr-16-21 Initiated
Goldman
Buy
$97
Mar-08-21 Upgrade
H.C. Wainwright
Neutral → Buy
$50
Dec-15-20 Downgrade
H.C. Wainwright
Buy → Neutral
Oct-06-20 Downgrade
Wells Fargo
Overweight → Equal Weight
Show Previous Ratings
Sep-06-24 09:30AM
Sep-03-24 05:00PM
Sep-02-24 06:15PM
Aug-27-24 04:36AM
Aug-16-24 05:00PM
07:15AM
Loading…
Aug-14-24 07:15AM
Aug-09-24 12:23PM
09:27AM
Aug-08-24 05:30PM
04:24PM
(Associated Press Finance)
04:01PM
Aug-01-24 10:01AM
Jul-31-24 05:31AM
Jul-29-24 06:24PM
04:01PM
08:31AM
Loading…
08:31AM
Jul-19-24 05:00PM
Jul-17-24 02:29PM
Jul-14-24 05:45AM
Jul-11-24 02:23PM
Jul-08-24 06:46PM
12:30PM
Jun-28-24 07:00AM
04:05AM
Jun-21-24 05:00PM
06:36AM
Jun-20-24 10:02PM
08:47PM
Jun-10-24 10:15AM
May-29-24 06:20AM
04:58AM
Loading…
04:58AM
May-28-24 08:14AM
08:06AM
May-24-24 04:01PM
11:18AM
May-23-24 05:00PM
May-22-24 06:40AM
May-17-24 05:15PM
May-16-24 09:30AM
May-13-24 02:25PM
12:42PM
May-11-24 10:00AM
May-10-24 02:03PM
01:35PM
12:55PM
12:33PM
11:25AM
10:58AM
May-09-24 08:57PM
04:27PM
(Associated Press Finance)
04:23PM
04:01PM
May-06-24 09:56AM
May-01-24 06:01AM
Apr-30-24 06:01AM
Apr-28-24 02:44PM
Apr-27-24 07:00AM
Apr-25-24 10:30AM
09:20AM
Apr-24-24 04:01PM
Apr-21-24 05:08AM
Apr-19-24 05:15PM
Apr-17-24 09:45AM
Apr-08-24 01:51PM
Apr-05-24 05:03AM
Mar-29-24 11:30AM
Mar-26-24 04:11AM
Mar-23-24 09:00AM
(The Wall Street Journal)
Mar-22-24 05:30PM
Mar-18-24 08:01PM
02:00AM
Mar-15-24 08:18AM
Mar-07-24 06:01AM
Mar-06-24 04:42AM
Mar-05-24 01:00PM
Mar-04-24 06:30AM
Mar-02-24 06:50AM
Mar-01-24 05:00PM
Feb-29-24 05:47PM
12:17PM
(Thomson Reuters StreetEvents)
10:37AM
09:44AM
05:51AM
Feb-28-24 05:35PM
04:42PM
(Associated Press Finance)
04:35PM
04:01PM
Feb-27-24 08:52AM
Feb-26-24 05:39AM
Feb-25-24 08:07AM
05:01AM
Feb-23-24 06:14AM
Feb-22-24 08:45AM
04:00AM
Feb-20-24 03:38PM
11:02AM
08:00AM
06:30AM
Feb-19-24 08:36AM
Feb-16-24 05:30PM
(GlobeNewswire) -7.29%
+31.48%
Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007, and is headquartered in San Carlos, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Vogt Frederick G Interim CEO & General Counsel Sep 03 '24 Option Exercise 0.00 57,292 0 212,175 Sep 05 07:56 PM GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer Sep 03 '24 Option Exercise 0.00 27,345 0 71,233 Sep 05 07:54 PM BILINSKY IGOR Chief Operating Officer Sep 03 '24 Option Exercise 0.00 26,954 0 66,313 Sep 05 07:53 PM Bellemin Jean-Marc Chief Financial Officer Sep 03 '24 Option Exercise 0.00 23,438 0 41,239 Sep 05 07:52 PM Vogt Frederick G Interim CEO & General Counsel Jul 15 '24 Option Exercise 0.00 20,835 0 168,160 Jul 17 08:01 PM GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer Jul 15 '24 Option Exercise 0.00 2,813 0 47,299 Jul 17 08:01 PM BILINSKY IGOR Chief Operating Officer Jul 15 '24 Option Exercise 0.00 2,813 0 42,571 Jul 17 08:00 PM GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer Jun 03 '24 Option Exercise 0.00 3,906 0 46,468 Jun 05 08:07 PM BILINSKY IGOR Chief Operating Officer Jun 03 '24 Option Exercise 0.00 3,516 0 41,542 Jun 05 08:05 PM Vogt Frederick G Interim CEO & General Counsel Jun 03 '24 Option Exercise 0.00 10,417 0 151,751 Jun 05 08:04 PM Vogt Frederick G Interim CEO & General Counsel Apr 15 '24 Option Exercise 0.00 20,834 0 150,185 Apr 17 07:08 PM GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer Apr 15 '24 Option Exercise 0.00 2,812 0 43,989 Apr 17 07:07 PM BILINSKY IGOR Chief Operating Officer Apr 15 '24 Option Exercise 0.00 2,812 0 39,453 Apr 17 07:07 PM GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer Mar 04 '24 Option Exercise 0.00 15,623 0 49,230 Mar 06 06:20 PM Vogt Frederick G Interim CEO & General Counsel Mar 04 '24 Option Exercise 0.00 41,662 0 140,800 Mar 06 06:19 PM MCPEAK MERRILL A Director Feb 20 '24 Buy 9.15 250,000 2,287,500 320,150 Feb 20 07:52 PM Dukes Iain D. Director Feb 20 '24 Buy 9.15 32,000 292,800 54,000 Feb 20 04:21 PM Rothbaum Wayne P. Director Feb 20 '24 Buy 9.15 5,000,000 45,750,000 28,067,333 Feb 20 04:11 PM Vogt Frederick G Interim CEO & General Counsel Jan 16 '24 Option Exercise 0.00 20,834 0 105,668 Jan 18 06:09 PM GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer Jan 16 '24 Option Exercise 0.00 2,813 0 35,184 Jan 18 06:09 PM BILINSKY IGOR Chief Operating Officer Jan 16 '24 Option Exercise 0.00 2,813 0 31,444 Jan 18 06:07 PM Vogt Frederick G Interim CEO & General Counsel Oct 16 '23 Option Exercise 0.00 20,835 0 93,685 Oct 18 08:05 PM BILINSKY IGOR Chief Operating Officer Oct 16 '23 Option Exercise 0.00 2,813 0 30,026 Oct 18 08:04 PM GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer Oct 16 '23 Option Exercise 0.00 2,813 0 33,766 Oct 18 08:03 PM MCPEAK MERRILL A Director Sep 18 '23 Buy 5.56 10,000 55,600 248,633 Sep 19 04:30 PM Rothbaum Wayne P. Director Sep 15 '23 Buy 5.30 5,000,000 26,500,000 23,067,333 Sep 15 06:12 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite